Investigators at Boston Children's Hospital Report Findings in Eosinophilic Esophagitis (The Role of Dupilumab In the Treatment of Eosinophilic Esophagitis).

A study conducted at Boston Children's Hospital has found that dupilumab, a fully human monoclonal antibody, has been approved by the US FDA for the treatment of eosinophilic esophagitis (EoE). Dupilumab inhibits IL-4 and IL-13 signaling, which are involved in the inflammation associated with EoE. Clinical trials have shown that dupilumab improves disease activity in EoE patients, and the treatment has a favorable safety profile. The study aims to review the available clinical trial data and real-world efficacy of dupilumab in treating EoE. [Extracted from the article]